| MeSH term | MeSH ID | Detail |
|---|---|---|
| Sarcoma, Ewing | D012512 | 2 associated lipids |
| Adrenal Hyperplasia, Congenital | D000312 | 2 associated lipids |
| Angina, Stable | D060050 | 2 associated lipids |
| Tooth Mobility | D014086 | 2 associated lipids |
| Urologic Neoplasms | D014571 | 2 associated lipids |
| Microvascular Angina | D017566 | 2 associated lipids |
| Otosclerosis | D010040 | 2 associated lipids |
| Root Resorption | D012391 | 2 associated lipids |
| Bacteroidaceae Infections | D016866 | 2 associated lipids |
| Bone Marrow Neoplasms | D019046 | 2 associated lipids |
7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Martin TJ and Mundy GR | Bone metastasis: can osteoclasts be excluded? | 2007 | Nature | pmid:17314931 |
| Locklin RM et al. | Agonists of TRAIL death receptors induce myeloma cell apoptosis that is not prevented by cells of the bone marrow microenvironment. | 2007 | Leukemia | pmid:17315027 |
| Ichimiya H et al. | Compressive mechanical stress promotes osteoclast formation through RANKL expression on synovial cells. | 2007 | Oral Surg Oral Med Oral Pathol Oral Radiol Endod | pmid:17321443 |
| Mancini L et al. | Calcitonin and prednisolone display antagonistic actions on bone and have synergistic effects in experimental arthritis. | 2007 | Am. J. Pathol. | pmid:17322385 |
| Mori K et al. | Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B. | 2007 | J. Pathol. | pmid:17323424 |
| Dovio A et al. | Increased osteoprotegerin levels in Cushing's syndrome are associated with an adverse cardiovascular risk profile. | 2007 | J. Clin. Endocrinol. Metab. | pmid:17327380 |
| Brechter AB and Lerner UH | Bradykinin potentiates cytokine-induced prostaglandin biosynthesis in osteoblasts by enhanced expression of cyclooxygenase 2, resulting in increased RANKL expression. | 2007 | Arthritis Rheum. | pmid:17328065 |
| Rouster-Stevens KA et al. | RANKL:osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis. | 2007 | Arthritis Rheum. | pmid:17328075 |
| Chen TH et al. | Sodium butyrate activates ERK to regulate differentiation of mesenchymal stem cells. | 2007 | Biochem. Biophys. Res. Commun. | pmid:17331472 |
| Mrak E et al. | Growth hormone stimulates osteoprotegerin expression and secretion in human osteoblast-like cells. | 2007 | J. Endocrinol. | pmid:17332531 |
| Kawashima N et al. | Kinetics of RANKL, RANK and OPG expressions in experimentally induced rat periapical lesions. | 2007 | Oral Surg Oral Med Oral Pathol Oral Radiol Endod | pmid:17336108 |
| Mori K and Jono S | [Calcified coronary artery disease and serum markers]. | 2007 | Clin Calcium | pmid:17339737 |
| Poubelle PE et al. | Differential expression of RANK, RANK-L, and osteoprotegerin by synovial fluid neutrophils from patients with rheumatoid arthritis and by healthy human blood neutrophils. | 2007 | Arthritis Res. Ther. | pmid:17341304 |
| Yamada A et al. | Interleukin-4 inhibition of osteoclast differentiation is stronger than that of interleukin-13 and they are equivalent for induction of osteoprotegerin production from osteoblasts. | 2007 | Immunology | pmid:17343616 |
| Cardús A et al. | Differential effects of vitamin D analogs on vascular calcification. | 2007 | J. Bone Miner. Res. | pmid:17352647 |
| Whyte MP et al. | Juvenile Paget's disease: the second reported, oldest patient is homozygous for the TNFRSF11B "Balkan" mutation (966_969delTGACinsCTT), which elevates circulating immunoreactive osteoprotegerin levels. | 2007 | J. Bone Miner. Res. | pmid:17352649 |
| Holecki M et al. | Osteoprotegerin--does it play a protective role in the pathogenesis of bone loss in obese perimenopausal women? | 2007 Jan-Feb | Endokrynol Pol | pmid:17354199 |
| Bostanci N et al. | Gingival crevicular fluid levels of RANKL and OPG in periodontal diseases: implications of their relative ratio. | 2007 | J. Clin. Periodontol. | pmid:17355365 |
| Gajewska J et al. | Osteoprotegerin and C-telopeptide of type I collagen in Polish healthy children and adolescents. | 2006 | Adv Med Sci | pmid:17357324 |
| Zauli G et al. | Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. | 2007 | Blood | pmid:17363729 |
| Knudsen ST et al. | Plasma concentrations of osteoprotegerin during normo- and hyperglycaemic clamping. | 2007 | Scand. J. Clin. Lab. Invest. | pmid:17365993 |
| Coon D et al. | The role of cyclooxygenase-2 (COX-2) in inflammatory bone resorption. | 2007 | J Endod | pmid:17368333 |
| Zhao G et al. | Requirement for both micron- and submicron scale structure for synergistic responses of osteoblasts to substrate surface energy and topography. | 2007 | Biomaterials | pmid:17368532 |
| Schlieper G et al. | Inhibitors of calcification in blood and urine. | 2007 Mar-Apr | Semin Dial | pmid:17374084 |
| Lappin DF et al. | Effect of smoking on serum RANKL and OPG in sex, age and clinically matched supportive-therapy periodontitis patients. | 2007 | J. Clin. Periodontol. | pmid:17378883 |
| Samadfam R et al. | Pretreatment with anticatabolic agents blunts but does not eliminate the skeletal anabolic response to parathyroid hormone in oophorectomized mice. | 2007 | Endocrinology | pmid:17379647 |
| Ominsky MS et al. | The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys. | 2007 | Osteoporos Int | pmid:17384898 |
| Beyens G et al. | Identification of sex-specific associations between polymorphisms of the osteoprotegerin gene, TNFRSF11B, and Paget's disease of bone. | 2007 | J. Bone Miner. Res. | pmid:17388729 |
| Jefferson AL et al. | Inflammatory biomarkers are associated with total brain volume: the Framingham Heart Study. | 2007 | Neurology | pmid:17389308 |
| Yonou H et al. | Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts. | 2007 | Prostate | pmid:17394194 |
| Monegal A et al. | Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation: relationship with metabolic bone disease. | 2007 | Liver Int. | pmid:17403189 |
| Sawajiri M et al. | Different effects of carbon ion and gamma-irradiation on expression of receptor activator of NF-kB ligand in MC3T3-E1 osteoblast cells. | 2006 | Bull. Exp. Biol. Med. | pmid:17415477 |
| Zofková I | [Osteoporosis and aterosclerosis--is there any pathogenetic association?]. | 2007 | Cas. Lek. Cesk. | pmid:17419308 |
| Michael H et al. | Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro. | 2007 | Br. J. Pharmacol. | pmid:17420779 |
| Harokopakis-Hajishengallis E | Physiologic root resorption in primary teeth: molecular and histological events. | 2007 | J Oral Sci | pmid:17429176 |
| Xiao HL et al. | Oral administration activity determination of recombinant osteoprotegerin from silkworm larvae. | 2007 | Mol. Biotechnol. | pmid:17435284 |
| Wang BL et al. | Recombinant soluble receptor activator of nuclear factor-kappaB inhibits parathyroid hormone-induced osteoclastogenesis in vitro. | 2007 | Sheng Li Xue Bao | pmid:17437039 |
| Schrader J et al. | Cytokine-induced osteoprotegerin expression protects pancreatic beta cells through p38 mitogen-activated protein kinase signalling against cell death. | 2007 | Diabetologia | pmid:17443309 |
| Giusti M et al. | Serum osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study. | 2007 | Metab. Clin. Exp. | pmid:17445547 |
| Taubman MA et al. | The new concept of periodontal disease pathogenesis requires new and novel therapeutic strategies. | 2007 | J. Clin. Periodontol. | pmid:17448041 |
| Belibasakis GN et al. | Regulation of RANKL and OPG gene expression in human gingival fibroblasts and periodontal ligament cells by Porphyromonas gingivalis: a putative role of the Arg-gingipains. | 2007 | Microb. Pathog. | pmid:17448630 |
| Zhu WQ et al. | Temporal and spatial expression of osteoprotegerin and receptor activator of nuclear factor -kappaB ligand during mandibular distraction in rats. | 2007 | J Craniomaxillofac Surg | pmid:17449257 |
| Keles A et al. | Inhibition of tooth movement by osteoprotegerin vs. pamidronate under conditions of constant orthodontic force. | 2007 | Eur. J. Oral Sci. | pmid:17451503 |
| Mountzios G et al. | Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. | 2007 | Acta Oncol | pmid:17453373 |
| Lin JM et al. | Alteration of bone cell function by RANKL and OPG in different in vitro models. | 2007 | Eur. J. Clin. Invest. | pmid:17461987 |
| Vaccarezza M et al. | A role of the TRAIL-TRAIL receptor system in the pathogenesis of diabetes. | 2007 | Acta Biomed | pmid:17465340 |
| Rausch-fan X et al. | Differentiation and cytokine synthesis of human alveolar osteoblasts compared to osteoblast-like cells (MG63) in response to titanium surfaces. | 2008 | Dent Mater | pmid:17467048 |
| Botella-Carretero JI et al. | Thyroid hormone deficiency and postmenopausal status independently increase serum osteoprotegerin concentrations in women. | 2007 | Eur. J. Endocrinol. | pmid:17468189 |
| Stern A et al. | The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study. | 2007 | Eur. J. Endocrinol. | pmid:17468191 |
| Omland T et al. | Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. | 2007 | Hypertension | pmid:17470718 |
| Iwasaki Y | [Uremic toxins and bone metabolism]. | 2007 | Clin Calcium | pmid:17471003 |
| Kapoor P et al. | Osteoprotegrin and the bone homing and colonization potential of breast cancer cells. | 2008 | J. Cell. Biochem. | pmid:17471510 |
| Silvestrini G et al. | Effects of the administration of corticosterone, parathyroid hormone, or both, and of their withdrawal, on rat bone and cartilage histomorphometric parameters, and on osteoprotegerin and RANKL mRNA expression and proteins. | 2007 | J. Mol. Histol. | pmid:17476578 |
| Celińska-Löwenhoff M et al. | Effects of hypolipemic drugs on the osteoprotegerin - sRANKL system in patients with coronary artery disease. | 2007 | Thromb. Haemost. | pmid:17479201 |
| Martinetti A et al. | Short-term effects of pamidronate on bone turnover: can bone markers be considered predictive of the analgesic response? | 2007 | Oncol. Rep. | pmid:17487415 |
| Kawai T et al. | Cross-reactive adaptive immune response to oral commensal bacteria results in an induction of receptor activator of nuclear factor-kappaB ligand (RANKL)-dependent periodontal bone resorption in a mouse model. | 2007 | Oral Microbiol. Immunol. | pmid:17488448 |
| Park H and Yim M | Rolipram, a phosphodiesterase 4 inhibitor, suppresses PGE2-induced osteoclast formation by lowering osteoclast progenitor cell viability. | 2007 | Arch. Pharm. Res. | pmid:17489366 |
| Lambert C et al. | Further insights in the mechanisms of interleukin-1beta stimulation of osteoprotegerin in osteoblast-like cells. | 2007 | J. Bone Miner. Res. | pmid:17501665 |
| Mora S et al. | Alterations in circulating osteoimmune factors may be responsible for high bone resorption rate in HIV-infected children and adolescents. | 2007 | AIDS | pmid:17502723 |
| Tanaka Y and Okada Y | [Progress in therapy and diagnosis: Hypercalcemia due to parathyroid hormone-related protein producing neoplasms]. | 2007 | Nippon Naika Gakkai Zasshi | pmid:17506302 |
| Kondo T et al. | Dexamethasone promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple levels. | 2008 | J. Cell. Biochem. | pmid:17516544 |
| Kim YD et al. | Effect of low-level laser treatment after installation of dental titanium implant-immunohistochemical study of RANKL, RANK, OPG: an experimental study in rats. | 2007 | Lasers Surg Med | pmid:17523169 |
| Messa P et al. | Calcimimetic increases osteoprotegerin and decreases fetuin-A levels in dialysis patients. | 2007 | Nephrol. Dial. Transplant. | pmid:17526536 |
| Baud'huin M et al. | RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases. | 2007 | Cell. Mol. Life Sci. | pmid:17530461 |
| Lau YS et al. | Cellular and humoral mechanisms of osteoclast formation in Ewing's sarcoma. | 2007 | Br. J. Cancer | pmid:17533390 |
| Méplan C et al. | Genetic polymorphisms in the human selenoprotein P gene determine the response of selenoprotein markers to selenium supplementation in a gender-specific manner (the SELGEN study). | 2007 | FASEB J. | pmid:17536041 |
| Chen HX et al. | [Serum osteoprotegerin as a novel marker of bone metastasis in prostate cancer]. | 2007 | Zhonghua Wai Ke Za Zhi | pmid:17537330 |
| Wara-aswapati N et al. | RANKL upregulation associated with periodontitis and Porphyromonas gingivalis. | 2007 | J. Periodontol. | pmid:17539720 |
| Kramer JM and Gaffen SL | Interleukin-17: a new paradigm in inflammation, autoimmunity, and therapy. | 2007 | J. Periodontol. | pmid:17539723 |
| Liu D and Wise GE | A DNA microarray analysis of chemokine and receptor genes in the rat dental follicle--role of secreted frizzled-related protein-1 in osteoclastogenesis. | 2007 | Bone | pmid:17540629 |
| Oelzner P et al. | Soluble receptor activator of NFkappa B-ligand and osteoprotegerin in rheumatoid arthritis - relationship with bone mineral density, disease activity and bone turnover. | 2007 | Clin. Rheumatol. | pmid:17541498 |
| Uemura H et al. | Circulating osteoprotegerin is associated with age and systolic blood pressure, but not with lipid profile or fasting glucose, in postmenopausal women. | 2008 Jan-Feb | Menopause | pmid:17545921 |
| Mangiafico RA et al. | Increased formation of 8-iso-prostaglandin F(2alpha) is associated with altered bone metabolism and lower bone mass in hypercholesterolaemic subjects. | 2007 | J. Intern. Med. | pmid:17547714 |
| Kiji M et al. | Internal prostaglandin synthesis augments osteoprotegerin production in human gingival fibroblasts stimulated by lipopolysaccharide. | 2007 | Clin. Exp. Immunol. | pmid:17550374 |
| Tatsumi S et al. | Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. | 2007 | Cell Metab. | pmid:17550781 |
| Joseph F et al. | The circadian rhythm of osteoprotegerin and its association with parathyroid hormone secretion. | 2007 | J. Clin. Endocrinol. Metab. | pmid:17550963 |
| Tan X et al. | Smad4 is required for maintaining normal murine postnatal bone homeostasis. | 2007 | J. Cell. Sci. | pmid:17550966 |
| Muñoz-Calvo MT et al. | Maintained malnutrition produces a progressive decrease in (OPG)/RANKL ratio and leptin levels in patients with anorexia nervosa. | 2007 | Scand. J. Clin. Lab. Invest. | pmid:17558893 |
| Bostanci N et al. | Differential expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin mRNA in periodontal diseases. | 2007 | J. Periodont. Res. | pmid:17559623 |
| Pi SH et al. | Defense mechanism of heme oxygenase-1 against cytotoxic and receptor activator of nuclear factor-kappaB ligand inducing effects of hydrogen peroxide in human periodontal ligament cells. | 2007 | J. Periodont. Res. | pmid:17559630 |
| Irie A et al. | Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity. | 2007 | Bone | pmid:17560185 |
| Tanishima S et al. | Minodronic acid influences receptor activator of nuclear factor kappaB ligand expression and suppresses bone resorption by osteoclasts in rats with collagen-induced arthritis. | 2007 | Mod Rheumatol | pmid:17564774 |
| Asanuma Y et al. | Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis. | 2007 | Atherosclerosis | pmid:17570371 |
| Miller RE et al. | Receptor activator of NF-kappa B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection. | 2007 | J. Immunol. | pmid:17579046 |
| Xia M et al. | [Expression and significance of nuclear factor-kappa B ligand and correlation factor in the tissue of otitis media with cholesteatoma]. | 2007 | Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi | pmid:17580719 |
| Nakao K et al. | Intermittent force induces high RANKL expression in human periodontal ligament cells. | 2007 | J. Dent. Res. | pmid:17586708 |
| Dunn MD et al. | Local delivery of osteoprotegerin inhibits mechanically mediated bone modeling in orthodontic tooth movement. | 2007 | Bone | pmid:17588510 |
| Simionescu A et al. | Osteogenic responses in fibroblasts activated by elastin degradation products and transforming growth factor-beta1: role of myofibroblasts in vascular calcification. | 2007 | Am. J. Pathol. | pmid:17591959 |
| Logar DB et al. | Expression of bone resorption genes in osteoarthritis and in osteoporosis. | 2007 | J. Bone Miner. Metab. | pmid:17593491 |
| Vik A et al. | Heparin induces mobilization of osteoprotegerin into the circulation. | 2007 | Thromb. Haemost. | pmid:17598007 |
| Geldyyev A et al. | High expression level of bone degrading proteins as a possible inducer of osteolytic features in pigmented villonodular synovitis. | 2007 | Cancer Lett. | pmid:17601661 |
| McCormick RK | Osteoporosis: integrating biomarkers and other diagnostic correlates into the management of bone fragility. | 2007 | Altern Med Rev | pmid:17604458 |
| Goranova-Marinova V et al. | Serum levels of OPG, RANKL and RANKL/OPG ratio in newly-diagnosed patients with multiple myeloma. Clinical correlations. | 2007 | Haematologica | pmid:17606458 |
| Vallés G et al. | Rutile and titanium particles differentially affect the production of osteoblastic local factors. | 2008 | J Biomed Mater Res A | pmid:17607761 |
| Jin Q et al. | RANKL inhibition through osteoprotegerin blocks bone loss in experimental periodontitis. | 2007 | J. Periodontol. | pmid:17608585 |
| Woo JH et al. | Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept. | 2007 | J. Rheumatol. | pmid:17610317 |
| Orita Y et al. | Role of osteoprotegerin in arterial calcification: development of new animal model. | 2007 | Arterioscler. Thromb. Vasc. Biol. | pmid:17615383 |
| Holt G et al. | The biology of aseptic osteolysis. | 2007 | Clin. Orthop. Relat. Res. | pmid:17620815 |
| Cibulka R et al. | Effect of L-carnitine supplementation on secondary hyperparathyroidism and bone metabolism in hemodialyzed patients. | 2007 | Calcif. Tissue Int. | pmid:17622482 |
| Vaccarezza M et al. | Increased OPG expression and impaired OPG/TRAIL ratio in the aorta of diabetic rats. | 2007 | Med Chem | pmid:17627577 |